U.S. Biopharmaceutical Market Size & Outlook, 2024-2030

The biopharmaceutical market in the United States is expected to reach a projected revenue of US$ 341,964.2 million by 2030. A compound annual growth rate of 7.9% is expected of the United States biopharmaceutical market from 2025 to 2030.
Revenue, 2024 (US$M)
$220,166.3
Forecast, 2030 (US$M)
$341,964.2
CAGR, 2025 - 2030
7.9%
Report Coverage
U.S.

U.S. biopharmaceutical market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

U.S. biopharmaceutical market, 2018-2030 (US$M)

U.S. biopharmaceutical market highlights

  • The U.S. biopharmaceutical market generated a revenue of USD 220,166.3 million in 2024 and is expected to reach USD 341,964.2 million by 2030.
  • The U.S. market is expected to grow at a CAGR of 7.9% from 2025 to 2030.
  • In terms of segment, monoclonal antibody was the largest revenue generating molecule type in 2024.
  • Hormone is the most lucrative molecule type segment registering the fastest growth during the forecast period.


Biopharmaceutical market data book summary

Market revenue in 2024USD 220,166.3 million
Market revenue in 2030USD 341,964.2 million
Growth rate7.9% (CAGR from 2025 to 2030)
Largest segmentMonoclonal antibody
Fastest growing segmentHormone
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationMonoclonal Antibody, Interferon, Insulin, Growth and Coagulation Factor, Erythropoietin, Vaccine, Hormone


Other key industry trends

  • In terms of revenue, U.S. accounted for 48.7% of the global biopharmaceutical market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In North America, U.S. biopharmaceutical market is projected to lead the regional market in terms of revenue in 2030.
  • Mexico is the fastest growing regional market in North America and is projected to reach USD 11,073.7 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Biopharmaceutical Market Companies

Name Profile # Employees HQ Website

U.S. biopharmaceutical market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical market will help companies and investors design strategic landscapes.


Monoclonal antibody was the largest segment with a revenue share of 66.96% in 2024. Horizon Databook has segmented the U.S. biopharmaceutical market based on monoclonal antibody, interferon, insulin, growth and coagulation factor, erythropoietin, vaccine, hormone covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to U.S. biopharmaceutical market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of U.S. biopharmaceutical market databook

  • Our clientele includes a mix of biopharmaceutical market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the U.S. biopharmaceutical market , including forecasts for subscribers. This country databook contains high-level insights into U.S. biopharmaceutical market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

U.S. biopharmaceutical market size, by molecule type, 2018-2030 (US$M)

U.S. Biopharmaceutical Market Outlook Share, 2024 & 2030 (US$M)

U.S. biopharmaceutical market size, by molecule type, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more